| Name | Title | Contact Details |
|---|
Autohuset Vestergaard A/S, Personvogne er blandt landets største bilvirksomheder. Vi har autoriseret salg af 11 bilmærker - Volvo, Polestar, Renault, KIA, Ford, Mazda, Dacia, Nissan, Maxus, JAC og BYD. Vi er repræsenteret med 12 filialer - Autohuset Vestergaard beskæftiger cirka 450 medarbejdere og sælger årligt mere end 15.000 nye og brugte biler. Vi er specialister inden for person- og varebiler til private og erhvervsdrivende. Autohuset Vestergaard skræddersyer en løsning, der matcher netop dit behov. Hvad end du ønsker at lease eller eje, så har vi løsningen til dig. Alle vores værksteder er ISO-certificerede og bemandet med top professionelle medarbejdere, der sikrer optimal pleje af din bil, uanset om det gælder service, reparation eller skadearbejde. Hos Autohuset Vestergaard er det vores målsætning, at skabe langsigtede relationer med vores kunder. I vores daglige arbejder bestræber vi os altid på at yde den indsats, der skal til, for at vi opnår yderst tilfredse kunder.
At Gate City Bank, we invest in the best people...driven people, compassionate people, creative people…people like you! We invest in the best team members because its whats best for our customers. We are investing in our team members with competitive compensation and comprehensive benefits packages, along with promoting a fun, family-friendly work environment. Gate City Bank is a mutual community bank and we have been providing complete banking services to our customers since 1923. It is Gate City Banks privilege to be a hometown bank that provides excellent service that is convenient, friendly, and personalized. We are proud to be the #1 mortgage lender in North Dakota with locally approved and financed home loans. Gate City Bank is also unique in offering our checking customers FREE ATMs anywhere with unlimited ATM fee refunds, which has saved our customers more than $33 million since we began refunding ATM fees in 2006. Thats what its all about here at Gate City Bank - making your financial life easier, more convenient, and more rewarding so you can enjoy a better way of life. Gate City Bank is honored to support our communities through charitable contributions, in-kind donations such as reduced interest-rate loans for non-profit organizations, and paid volunteer time for our team members. We go beyond our commitment to offering the best checking, savings, and loan programs – were touching lives in the communities we serve. With 43 locations across North Dakota and central Minnesota, Gate City Bank shares a commitment to our customers, communities, and team members. Member FDIC - Equal Housing Lender - EOE, including Disability/Vets
Cox PLLC exists to serve you and your company. We are litigators, counselors and trial attorneys. Our clients hire us to aggressively preserve or grow equity, eliminate risk and resolve disputes. We are available anytime and anywhere.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.